News | Heart Valve Technology | November 10, 2015

First Pennsylvania Patient Treated in Next Generation Aortic Heart Valve Study

Trial at PinnacleHealth CardioVascular Institute compares Direct Flow Medical TAVR device to Medtronic CoreValve

SALUS trial, Direct Flow Medical TAVR device, Medtronic CoreValve, PinnacleHealth CardioVascular Institute

Image courtesy of Direct Flow Medical


November 10, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a randomized trial studying a new heart valve to treat aortic valve disorders. Harrisburg Hospital is the only trial site in Pennsylvania. This study represents the next wave of research with aortic valves that conform to the patient's anatomy.

According to an article published in the Journal of the American College of Cardiology, aortic stenosis (AS) is the most common valvular heart disease in developed countries with prevalence estimated between 3 and 23 percent. AS mainly affects older people, due to scarring and calcium buildup in the valve cusp. With a growing elderly population, AS is anticipated to become a major public health concern.

SALUS is a prospective, multicenter clinical trial of the Direct Flow Medical Transcatheter Aortic Valve System, which will enroll 912 subjects in up to 45 sites in the United States. Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery, and William Bachinsky, M.D., FACC, medical director of vascular services, serve as co-principal investigators locally at PinnacleHealth.

"Our team of cardiologists and cardiovascular surgeons has a long-standing reputation for treating complex heart conditions," said Mumtaz. "We feel it is our mission to continually assess new, innovative options for our patients."

The purpose of SALUS is to compare the Direct Flow Medical system to the commercially available Medtronic CoreValve in high- and extreme-risk patients with severe symptomatic aortic stenosis. The Direct Flow Medical valve has a double-ring, polymer-based frame, while the Medtronic CoreValve is held by a metal frame. The unique design of the investigational device allows the valve to conform to the patient's anatomy. Unlike other transcatheter aortic valve replacement procedures, the investigational valve does not require rapid pacing of the heart through electrical stimulation.

At PinnacleHealth, there is a team approach to transcatheter aortic valve replacement (TAVR) procedures. TAVR procedures, such as those using Direct Flow Medical and CoreValve valves, involve direct care by both a cardiothoracic surgeon and interventional cardiologist in a specially equipped operating room. 

For more information: www.pinnaclehealth.org


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now